Microbiome Therapeutics MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy IndicationBy Route of AdministrationBy Source of MicrobiotaBy Development StageBy Therapeutic AreaBy Dosage FormBy Patient Age GroupBy Regulatory PathwayBy End UserBy Distribution Channel
Full title & scope — all 11 axes with their segments
Microbiome Therapeutics Market Size, Share & Industry Analysis, By Product Type (Live Biotherapeutic Products, Fecal Microbiota Products, Microbiome-Derived Small Molecules and Metabolites, Prebiotic-Based Therapeutics, Bacteriophage Therapeutics, Microbiome-Targeted Biologics and Antimicrobials), By Indication (Clostridioides difficile Infection, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Metabolic Disorders, Oncology and Immuno-Oncology, Dermatological Conditions, Neurological and CNS Disorders, Vaginal and Urogenital Infections, Other Indications), By Route of Administration (Oral, Rectal, Topical, Vaginal, Nasogastric/Nasoduodenal), By Source of Microbiota (Human Donor-Derived, Cultured Isolate-Derived, Synthetically Engineered, Food-Derived), By Development Stage (Approved and Marketed, Phase III, Phase II, Phase I, Preclinical), By Therapeutic Area (Gastroenterology, Infectious Diseases, Metabolic and Endocrine, Oncology, Dermatology, Neurology, Women's Health), By Dosage Form (Capsules, Liquid Suspensions, Powders, Topical Formulations, Tablets), By Patient Age Group (Adults, Geriatric, Paediatric), By Regulatory Pathway (Biologic (BLA/Drug) Pathway, Medicinal Product (EMA/MAA) Pathway, Enforcement Discretion/Special Access, Hospital Exemption), By End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, Homecare Settings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies), and Regional Forecast, 2026-2034
Talk to the analyst who built the estimates, and shape the scope around your question.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Microbiome Therapeutics Market projected to reach?
USD 1690 USD Million by 2034, CAGR 22.42%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 53% of global revenue through 2034.
05Which segment leads the market?
Live Biotherapeutic Products (LBPs) is the largest line by product type, at 38% of revenue in 2025.
06Who are the key companies profiled?
Ferring Pharmaceuticals, Seres Therapeutics, Inc., Nestlé Health Science, Vedanta Biosciences, Inc., MaaT Pharma SA, Finch Therapeutics Group, Inc., Microbiotica Ltd, Destiny Pharma plc, 4D Pharma plc, Evelo Biosciences, Inc., Kaleido Biosciences, Inc., AOBiome Therapeutics, Inc., Osel, Inc., Rebiotix Inc., Assembly Biosciences, Inc., Enterome SA, Genome & Company, Siolta Therapeutics, Inc., Exeliom Biosciences, NuBiyota, Biomica Ltd, Servatus Ltd, Taisho Pharmaceutical Co., Ltd., Sanofi S.A., Danone S.A., Sun Pharmaceutical Industries Ltd., Genetic Analysis AS, Federation Bio. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.